Figure 1.
Clear cell renal cell carcinoma is characterized by substantial genomic heterogeneity during tumor development. Potential approaches to identify targeted therapy could involve multi-region exome sequencing (M-Seq) of multiple primary tumor foci to identify common driver mutations. Alternatively, or in addition, tumors from metastatic sites could undergo sequence analysis to identify driver mutations essential for the development of metastases.